BCAX

Bicara Therapeutics Inc. Common Stock

Fundamental data last updated:November 17, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

03/29/2027

Business Summary

Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.

 


VALUATION

P/E

-2.93

Market Cap ($M USD)

$673.64M

Forward P/E

21.03

PEG

-0.08

PRICE TO SALES

0.00

PRICE TO BOOK

1.70

EV / EBITDA

-2.64

5-Year Average P/E

Free Cash Flow Yield

-24.16%

DCF Value

$1.60

Graham Number

N/A

Price to FCF

-4.14

EV to FCF

-3.64

Earnings Yield

-31.65%

FCF Yield

-24.16%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$3.22

Next Year EPS Growth Estimate

-$3.42

Next Year Revenue Growth Estimate

$0.00

Return on Equity (ROE)

-49.13%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.00

Piotroski F-Score

2

Altman Z-Score

5.53

Return on Invested Capital (ROIC)

-57.77%

Current Ratio

8.81

Quick Ratio

8.81

Net Debt to EBITDA

0.36

Interest Coverage

0.00

Gross Profit margin

0.00%

FCF PER SHARE

$-2.38

REVENUE PER SHARE

$0.00

Gainseekers Quantitative Analysis

Summary

BCAX’s valuation is a paradox. Despite a staggering market cap, the stock’s price has been trading significantly above its DCF value, suggesting a potential overvaluation. The Forward P/E of 25.31 implies optimism about future earnings, yet the negative Earnings Yield and ROIC highlight inefficiencies and potential risks. However, the Altman Z-score of 25.06 indicates financial stability, suggesting the company is not in immediate distress. The market seems to be pricing in a turnaround, but the numbers tell a more cautious tale.

AI Exposure / Tech Reliance

In the biotechnology sector, BCAX is well-positioned to leverage AI for drug discovery and personalized medicine. The industry's rapid tech adoption could enhance R&D efficiency and speed to market. However, execution remains key to capitalizing on these technological shifts.

The Bull Case

For the bullish investor, BCAX presents an intriguing opportunity. The Forward PEG ratio of 0.19 suggests undervaluation relative to growth, while the negligible Debt/Equity ratio indicates a strong balance sheet. Despite a low Piotroski F-Score, the high Current Ratio of 14.58 reflects robust liquidity. These factors, combined with a consensus "Buy" rating, paint a picture of potential upside for those willing to bet on future growth.

The Bear Case

On the flip side, BCAX's structural weaknesses are glaring. The negative Price to FCF and Earnings Yield highlight poor cash flow generation, raising red flags about operational efficiency. Trading near its 52-week high, the stock appears technically overextended, risking a pullback. Additionally, the Price/Book ratio of 3.10 suggests the market may be overvaluing its assets, especially given the lack of profitability and zero gross margins.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$31.57

Institutional Ownership %

1-Year Beta

-0.82

Insider Buying % (6 Mo)

Distance to 52-Week High

204.42%

Distance to 52-Week Low

22.69%

EARNINGS SURPRISE %

-26.83%

50-DAY SMA

$17.89

200-DAY SMA

$20.96

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.